NCT06091579View on ClinicalTrials.gov

A Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Treprostinil Palmitil Inhalation Powder (TPIP) in Healthy Participants

PHASE1CompletedINTERVENTIONAL
Enrollment

42

Participants

Timeline

Start Date

September 17, 2020

Primary Completion Date

January 12, 2021

Study Completion Date

January 12, 2021

Conditions
Healthy Volunteers
Interventions
DRUG

Treprostinil Palmitil Inhalation Powder

Oral inhalation using a Plastiape capsule-based dry powder inhaler.

DRUG

Placebo

Oral placebo inhalation using a Plastiape capsule-based dry powder inhaler.

Trial Locations (1)

78744

USA001, Austin

All Listed Sponsors
lead

Insmed Incorporated

INDUSTRY

NCT06091579 - A Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Treprostinil Palmitil Inhalation Powder (TPIP) in Healthy Participants | Biotech Hunter | Biotech Hunter